Yousif Capital Management LLC Has $444,000 Stock Position in Takeda Pharmaceutical Co. (NYSE:TAK)

Yousif Capital Management LLC lowered its holdings in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 37.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,869 shares of the company's stock after selling 18,250 shares during the period. Yousif Capital Management LLC's holdings in Takeda Pharmaceutical were worth $444,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Farther Finance Advisors LLC boosted its stake in shares of Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after purchasing an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. bought a new position in shares of Takeda Pharmaceutical in the fourth quarter valued at about $52,000. Cromwell Holdings LLC bought a new stake in Takeda Pharmaceutical during the 4th quarter worth about $61,000. Venturi Wealth Management LLC raised its holdings in Takeda Pharmaceutical by 554.7% during the 4th quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock worth $67,000 after purchasing an additional 4,260 shares during the last quarter. Finally, Lindbrook Capital LLC increased its stake in shares of Takeda Pharmaceutical by 65.0% in the 4th quarter. Lindbrook Capital LLC now owns 5,151 shares of the company's stock valued at $68,000 after acquiring an additional 2,029 shares during the last quarter. Institutional investors and hedge funds own 9.17% of the company's stock.

Takeda Pharmaceutical Price Performance

Shares of TAK opened at $14.75 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.52 and a current ratio of 1.01. The stock has a 50 day simple moving average of $14.79 and a 200 day simple moving average of $14.20. Takeda Pharmaceutical Co. has a 52-week low of $12.60 and a 52-week high of $15.43. The firm has a market capitalization of $46.92 billion, a PE ratio of 67.03 and a beta of 0.23.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 10.64% and a net margin of 2.36%. The firm had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. Sell-side analysts predict that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co. (NYSE:TAK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.